Azeliragon (Standaard)

Azeliragon (Standard) is the analytical standard of Azeliragon. This product is intended for research and analytical applications. Azeliragon (TTP488) is an orally bioavailable inhibitor of the receptor for advanced glycation end products (RAGE) in development as a potential treatment to slow disease progression with mild Alzheimer’s disease (AD) [1]. Azeliragon also can cross the blood-brain barrier (BBB) [2].

603148-36-3

12352100

Amyloid-β; Reference Standards

Neuronal Signaling; Others

Neurological Disease; Cancer

ClC1=CC=C(C=C1)OC2=CC=C(C=C2)N3C(CCCC)=NC(C(C=C4)=CC=C4OCCCN(CC)CC)=C3

C32H38ClN3O2

532.12

[1]Burstein AH, et al. Assessment of Azeliragon QTc Liability Through Integrated, Model-Based Concentration QTc Analysis. Clin Pharmacol Drug Dev. 2019 May;8 (4) :426-435.|[2]Bongarzone S, et al. Targeting the Receptor for Advanced Glycation Endproducts (RAGE) : A Medicinal Chemistry Perspective. J Med Chem. 2017 Sep 14;60 (17) :7213-7232.|[3]Chen Y, et al. RAGE ligation affects T cell activation and controls T cell differentiation. J Immunol. 2008 Sep 15;181 (6) :4272-8.

Room temperature

http://file.medchemexpress.com/batch_PDF/HY-50682R/

Reference Standards